MDS patients also have lower levels of plasmatic TAS (0.97 mM (0.81–1.09), p = 0.005) and erythrocytic GSH (6.54 μmol/g Hb (5.61–7.44), p = 0.022) than controls (TAS: 1.22 mM (0.91–1.32); GSH: 8.16 μmol/g Hb (6.58–8.61)). The gene discussed is GSTM1; the disease is myelodysplastic syndrome.